BRISTOL MYERS SQUIBB CO (BMY) vs JOHNSON & JOHNSON (JNJ)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | BMY | JNJ |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $48.19B | $94.19B |
| Revenue growth (YoY) | ▼ 0.2% | ▲ 6.0% |
| Net income | $7.05B | $26.8B |
| Gross margin | 71.1% | 67.9% |
| Diluted EPS | $3.46 | $11.03 |
| Insider net (6 mo) | +54.4K sh • 3 sells • 0 buys | −55.1K sh • 7 sells • 0 buys |
| Institutional owners | 64 | 67 |
| Institutional value held | $65.66B | $304.18B |
| Next earnings (est.) | Feb 4, 2027 | Around Jan 20, 2027 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About BRISTOL MYERS SQUIBB CO (BMY)
Bristol-Myers Squibb Company (BMS) is a global biopharmaceutical company that discovers, develops, licenses, manufactures, markets, distributes and sells innovative medicines for patients with serious diseases. Read more →
About JOHNSON & JOHNSON (JNJ)
Johnson & Johnson is a holding company, incorporated in New Jersey in 1887, whose operating companies research, develop, manufacture and sell a broad range of products in the healthcare field, with a primary focus on human health and well-being. Read more →
Source: SEC EDGAR.